ACXP - Acurx's Antibiotic Shows All Patients With Clinical Cure Remained Infection-Free After End Of Treatment | Benzinga
Acurx Pharmaceuticals Inc (NASDAQ: ACXP) released Phase 2b results showing 100% of C. difficile Infection (CDI) patients who had clinical cure (CC) with ibezapolstat, also had Sustained Clinical Cure (SCC).
All 15 ibezapolstat-treated patients in Phase 2b who achieved Clinical Cure (CC) at the end of treatment (EOT) remained free of C. difficile Infection (CDI) recurrence through one month after EOT for a Sustained Clinical Cure (SCC) rate of 100%.
2 of 14 patients treated with ...